Literature DB >> 26468294

Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress.

Leticia Y Peche1, María F Ladelfa2, María F Toledo2, Miguel Mano3, Julieta E Laiseca2, Claudio Schneider4, Martín Monte5.   

Abstract

MageB2 belongs to the melanoma antigen gene (MAGE-I) family of tumor-specific antigens. Expression of this gene has been detected in human tumors of different origins. However, little is known about the protein function and how its expression affects tumor cell phenotypes. In this work, we found that human MageB2 protein promotes tumor cell proliferation in a p53-independent fashion, as observed both in cultured cells and growing tumors in mice. Gene expression analysis showed that MageB2 enhances the activity of E2F transcription factors. Mechanistically, the activation of E2Fs is related to the ability of MageB2 to interact with the E2F inhibitor HDAC1. Cellular distribution of MageB2 protein includes the nucleoli. Nevertheless, ribotoxic drugs rapidly promote its nucleolar exit. We show that MageB2 counteracts E2F inhibition by ribosomal proteins independently of Mdm2 expression. Importantly, MageB2 plays a critical role in impairing cell cycle arrest in response to Actinomycin D. The data presented here support a relevant function for human MageB2 in cancer cells both under cycling and stressed conditions, presenting a distinct functional feature with respect to other characterized MAGE-I proteins.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E2F transcription factor; cancer biology; cell proliferation; histone deacetylase 1 (HDAC1); molecular cell biology

Mesh:

Substances:

Year:  2015        PMID: 26468294      PMCID: PMC4705963          DOI: 10.1074/jbc.M115.671982

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.

Authors:  Christine P Hans; Dennis D Weisenburger; Julie M Vose; Lynette M Hock; James C Lynch; Patricia Aoun; Timothy C Greiner; Wing C Chan; Robert G Bociek; Philip J Bierman; James O Armitage
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

Review 2.  E2F1 and c-Myc in cell growth and death.

Authors:  Itaru Matsumura; Hirokazu Tanaka; Yuzuru Kanakura
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

3.  Regulation of E2F1 function by the nuclear corepressor KAP1.

Authors:  Chuangui Wang; Frank J Rauscher; W Douglas Cress; Jiandong Chen
Journal:  J Biol Chem       Date:  2007-08-17       Impact factor: 5.157

4.  MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.

Authors:  Björn F Krämer; Oliver Schoor; Tobias Krüger; Christian Reichle; Margret Müller; Toni Weinschenk; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanovic
Journal:  Cancer Biol Ther       Date:  2005-09-08       Impact factor: 4.742

5.  Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.

Authors:  Roza K Sypniewska; Lieve Hoflack; Melissa Tarango; Susan Gauntt; Belinda Z Leal; Robert L Reddick; Claudia Gravekamp
Journal:  Breast Cancer Res Treat       Date:  2005-05       Impact factor: 4.872

6.  Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo.

Authors:  Bing Yang; Sean O'Herrin; Jianqiang Wu; Shannon Reagan-Shaw; Yongsheng Ma; Minakshi Nihal; B Jack Longley
Journal:  J Invest Dermatol       Date:  2006-09-07       Impact factor: 8.551

7.  Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.

Authors:  Shifeng Su; John T Minges; Gail Grossman; Amanda J Blackwelder; James L Mohler; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2013-07-12       Impact factor: 5.157

8.  Sin3B: an essential regulator of chromatin modifications at E2F target promoters during cell cycle withdrawal.

Authors:  Kathryn B Grandinetti; Gregory David
Journal:  Cell Cycle       Date:  2008-04-01       Impact factor: 4.534

9.  MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma.

Authors:  Kavita M Pattani; Ethan Soudry; Chad A Glazer; Michael F Ochs; Hao Wang; Juliana Schussel; Wenyue Sun; Patrick Hennessey; Wojciech Mydlarz; Myriam Loyo; Semra Demokan; Ian M Smith; Joseph A Califano
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression.

Authors:  Monica Fedele; Giovanna Maria Pierantoni; Rosa Visone; Alfredo Fusco
Journal:  Cell Div       Date:  2006-08-17       Impact factor: 5.130

View more
  12 in total

Review 1.  Targeting the epigenome in malignant pleural mesothelioma.

Authors:  Kaitlin C McLoughlin; Andrew S Kaufman; David S Schrump
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Cancer/testis antigens as molecular drug targets using network pharmacology.

Authors:  Anuj Kumar; Drista Sharma; M L Aggarwal; K M Chacko; Tarun Kumar Bhatt
Journal:  Tumour Biol       Date:  2016-10-05

Review 3.  A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.

Authors:  Anna K Lee; Patrick Ryan Potts
Journal:  J Mol Biol       Date:  2017-03-11       Impact factor: 5.469

Review 4.  Deciphering the Role of the Barr Body in Malignancy: An insight into head and neck cancer.

Authors:  Deepti Sharma; George Koshy; Shruti Gupta; Bhushan Sharma; Sonal Grover
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

Review 5.  Emerging roles of the MAGE protein family in stress response pathways.

Authors:  Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts
Journal:  J Biol Chem       Date:  2020-09-13       Impact factor: 5.157

6.  Functional interaction between co-expressed MAGE-A proteins.

Authors:  Julieta E Laiseca; María F Ladelfa; Javier Cotignola; Leticia Y Peche; Franco A Pascucci; Bryan A Castaño; Mario D Galigniana; Claudio Schneider; Martin Monte
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

7.  Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.

Authors:  Maria R Ward Rashidi; Pooja Mehta; Michael Bregenzer; Shreya Raghavan; Elyse M Fleck; Eric N Horst; Zainab Harissa; Visweswaran Ravikumar; Samuel Brady; Andrea Bild; Arvind Rao; Ronald J Buckanovich; Geeta Mehta
Journal:  Neoplasia       Date:  2019-07-09       Impact factor: 5.715

Review 8.  Role and Clinical Utility of Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma.

Authors:  Sharon Changshan Wu; Karl Münger
Journal:  Cancers (Basel)       Date:  2021-11-14       Impact factor: 6.639

9.  Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.

Authors:  Tiziana de Cristofaro; Tina Di Palma; Amata Amy Soriano; Antonella Monticelli; Ornella Affinito; Sergio Cocozza; Mariastella Zannini
Journal:  Oncotarget       Date:  2016-07-05

10.  Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.

Authors:  P Fan; Y Zhang; L Liu; Z Zhao; Y Yin; X Xiao; N Bauer; J Gladkich; J Mattern; C Gao; P Schemmer; W Gross; I Herr
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.